Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease

IF 6.2 Q1 IMMUNOLOGY

ImmunoTargets and Therapy Pub Date : 2023-12-01 DOI:10.2147/itt.s445971

Chrong-Reen Wang, Wei-Chieh Lin, T. Wong

引用次数: 0

查看原文本刊更多论文

对一名患有早期间质性肺病的 MDA5 抗体阳性肌病性皮肌炎患者的缓释托法替尼疗法

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ImmunoTargets and Therapy IMMUNOLOGY-

CiteScore

16.50

自引率

0.00%

发文量

审稿时长

16 weeks

期刊介绍： Immuno Targets and Therapy is an international, peer-reviewed open access journal focusing on the immunological basis of diseases, potential targets for immune based therapy and treatment protocols employed to improve patient management. Basic immunology and physiology of the immune system in health, and disease will be also covered.In addition, the journal will focus on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction.